(Total Views: 302)
Posted On: 06/20/2019 12:51:10 PM
Post# of 149303
CYDY lowered price for Leronlimab to $ 35,000, at the same time NP says BP returned to negotiating table
With lower price and approved combo, Leronlimab can be used off-label and compete with Gilead and others before the mono is approved
This is a good plan and thus pressing BP and before the mono is approved, off-label is most common in HIV, cancers and pediatrics
With lower price and approved combo, Leronlimab can be used off-label and compete with Gilead and others before the mono is approved
This is a good plan and thus pressing BP and before the mono is approved, off-label is most common in HIV, cancers and pediatrics
(1)
(0)Scroll down for more posts ▼
